170 related articles for article (PubMed ID: 19880845)
1. Treatment of anemia in chronic kidney disease--strategies based on evidence.
Marsden PA
N Engl J Med; 2009 Nov; 361(21):2089-90. PubMed ID: 19880845
[No Abstract] [Full Text] [Related]
2. Darbepoetin alfa and chronic kidney disease.
Locatelli F; Del Vecchio L; Casartelli D
N Engl J Med; 2010 Feb; 362(7):654-5; author reply 655. PubMed ID: 20187259
[No Abstract] [Full Text] [Related]
3. Erythropoiesis-stimulating agents--time for a reevaluation.
Unger EF; Thompson AM; Blank MJ; Temple R
N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
[No Abstract] [Full Text] [Related]
4. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).
Goldsmith D; Covic A
Nephrol Dial Transplant; 2010 Jun; 25(6):1734-7. PubMed ID: 20200007
[No Abstract] [Full Text] [Related]
5. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
6. An ongoing study of anemia correction in chronic kidney disease.
Pfeffer MA;
N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707
[No Abstract] [Full Text] [Related]
7. Darbepoetin alfa and chronic kidney disease.
Wright RJ; Kanagasundaram NS; Quinton R
N Engl J Med; 2010 Feb; 362(7):653; author reply 655. PubMed ID: 20164489
[No Abstract] [Full Text] [Related]
8. Darbepoetin alfa and chronic kidney disease.
Hampl H; Kovesdy CP; Kalantar-Zadeh K
N Engl J Med; 2010 Feb; 362(7):654; author reply 655. PubMed ID: 20187260
[No Abstract] [Full Text] [Related]
9. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
[TBL] [Abstract][Full Text] [Related]
10. Chronic kidney disease anemia management: what should be done?
Szczech LA
Blood Purif; 2011; 31(1-3):186-8. PubMed ID: 21228588
[TBL] [Abstract][Full Text] [Related]
11. Anemia management in chronic kidney disease: bursting the hemoglobin bubble.
Weiner DE; Miskulin DC
Ann Intern Med; 2010 Jul; 153(1):53-5. PubMed ID: 20439567
[No Abstract] [Full Text] [Related]
12. Erythropoietin in kidney disease and type 2 diabetes.
Locatelli F; Del Vecchio L; Casartelli D
N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268745
[No Abstract] [Full Text] [Related]
13. Chronic kidney disease, anemia, and epoetin.
Go AS; Ayus JC
N Engl J Med; 2007 Mar; 356(9):957; author reply 958-9. PubMed ID: 17338046
[No Abstract] [Full Text] [Related]
14. Anemia in the older adult. Engineering George's road to better health.
Henderson MJ
Adv Nurse Pract; 2007 Jun; 15(6):55-6, 58. PubMed ID: 19999010
[No Abstract] [Full Text] [Related]
15. Anemia management in CKD patients in the era of new US Food and Drug Administration recommendations on the use of erythropoiesis-stimulating agents.
Kaufman JS
Am J Kidney Dis; 2013 Feb; 61(2):191-3. PubMed ID: 23318011
[No Abstract] [Full Text] [Related]
16. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
[TBL] [Abstract][Full Text] [Related]
18. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
Milovanov IuS; Milovanova LIu
Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa and chronic kidney disease.
Minnerup J; Schäbitz WR
N Engl J Med; 2010 Feb; 362(7):653-4; author reply 655. PubMed ID: 20187258
[No Abstract] [Full Text] [Related]
20. Management of anemia in patients with kidney disease in 2013 and beyond.
Wish JB
Nephrol News Issues; 2013 Jun; 27(7):Supp 1-3. PubMed ID: 23855140
[No Abstract] [Full Text] [Related]
[Next] [New Search]
